TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00463385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to pomalidomide
Description: Matching pomalidomide placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to prednisone
Description: Matching prednisone placebo tablets
Study: NCT04047459

Intervention type: OTHER
Intervention: Tissue samples collection and cells isolation
Description: During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
Study: NCT00711165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: 400 mcg, qd for 8 weeks
Study: NCT02333110

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spatially fractionated radiation therapy
Description: A single dose of 15-20Gys of spatially fractionated radiation therapy
Study: NCT03015168

Intervention type: RADIATION
Intervention: capecitabine and concurrent intensity modulated radiotherapy
Description: patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
Study: NCT02679716

Intervention type: OTHER
Group type: OTHER
Intervention: MRI of the cerebral arteries
Description: MRI of the cerebral arteries is performed
Study: NCT00003726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lepirudin
Description: lepirudin
Study: NCT01286896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses.
Study: NCT00594568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily
Study: NCT04244162

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Imaging
Description: Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive testing
Description: Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Biomarkers
Description: Inflammatory markers
Study: NCT00319488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Corticosteroid (Budesonide)
Description: Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leukotriene Receptor Antagonist (Montelukast Sodium)
Description: Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Albuterol
Description: All participants will receive inhaled albuterol treatments four times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Albuterol
Description: All participants will receive inhaled albuterol treatments four times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Albuterol
Description: All participants will receive inhaled albuterol treatments four times a day.
Study: NCT01284413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Gemcitabine, Cisplatin
Description: S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
Study: NCT02793258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session.
Study: NCT03696420

Intervention type: OTHER
Intervention: Coordinates of active plots and VIM landmarks calculation
Description: Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
Study: NCT01655784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coil Embolization with larger Diameter Coils
Description: Eighteen Coils placed in cerebral aneurysm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coil Embolization with Standard Diameter Coils
Description: Cerebral aneurysms will be embolized with standard diameter coils.
Study: NCT01074853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: 10mg twice daily escalated to 80mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo
Study: NCT04650178

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT02127788

Intervention type: DRUG
Intervention: Micafungin
Description: intravenous
Study: NCT00276458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin
Description: Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo
Description: Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ezetimibe
Description: Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo.
Description: Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
Study: NCT01111968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 1
Description: 7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 2
Description: 3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 5
Description: 7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 6
Description: 3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
Study: NCT01145846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine plus Daunorubicin [Arm II (AD regimen)]
Description: Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
Study: NCT01111968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 9
Description: 7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 10
Description: 3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandmeic vaccine 11
Description: 7,5µg of A/H1N1 with Al(OH)3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandmeic vaccine 12
Description: 3,75µg of A/H1N1 with Al(OH)3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandmic vaccine 13
Description: 15µg of A/H1N1 with no adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo group 14
Description: All elements of the vaccine but antigen and adjuvant
Study: NCT01907516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell phone-internet home glucose reporting system
Description: Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cell phone-internet home glucose reporting system
Description: Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voicemail home blood glucose reporting
Description: Glucose monitoring via standard telephone and fax reporting.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Voicemail home blood glucose reporting
Description: Glucose monitoring via standard telephone and fax reporting.
Study: NCT04587154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-fat vegan diet with 1/2 cup soybeans daily
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet with 1/2 cup of soybeans daily.
Study: NCT02985476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health reports
Description: Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
Study: NCT00828139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: Given IV
Study: NCT00518596

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplementation (Lactobacillus plantarum)
Description: GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
Study: NCT04614480

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
Study: NCT02774577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training in vibrating platform in young

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training in vibrating platform in elderly
Study: NCT01572610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: once a day, oral administration
Study: NCT00934518

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
Study: NCT01853215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T.A.L.O.N. Intraosseous System
Description: intraosseous catheter for use in the sternum
Study: NCT00934518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation
Study: NCT00794222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Tracking Young People's Experiences (mobiletype)
Description: A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
Study: NCT01542801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norfloxacin 400 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: Ciprofloxacin 750 mg per week
Study: NCT00200863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic visible light exposure
Description: Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic visible light exposure
Description: Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic visible light exposure
Description: Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic visible light exposure
Description: Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
Study: NCT03953157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive dietary intervention
Study: NCT01485159

Intervention type: PROCEDURE
Intervention: Spirometry
Description: assessment of lung function by spirometry
Study: NCT03154385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera ®) Belimumab (Benlysta ®)
Description: Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
Study: NCT00200863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic visible light exposure
Description: Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
Study: NCT04400058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo
Study: NCT00837200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncaspar, Doxil, Decadron
Description: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
Study: NCT03592316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Amputation Pathway
Description: Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care.
Study: NCT03926429

Intervention type: OTHER
Intervention: Standardised data collection
Description: The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
Study: NCT04838730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical procedure
Description: Standard cataract extraction procedure will be performed under local anesthesia (at physician discretion) and CleaRing device will be implanted together with SeeLens AF IOL.
Study: NCT02251093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lcr Regenerans
Description: Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
Study: NCT01497028

Intervention type: PROCEDURE
Intervention: PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
Description: PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.

Intervention type: PROCEDURE
Intervention: PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
Description: PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
Study: NCT00624273

Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil therapy
Description: oral use
Study: NCT02182934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsana

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01541046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biogaia L. reuteri DSM 17938
Description: Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Placebo
Description: Description of Placebo: contains same excipients as Active Agent, without the active ingredient
Study: NCT00518596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus plantarum)
Description: GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
Study: NCT00370747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet
Description: ophthalmic solution 2.83%
Study: NCT02600975

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with ASO1B
Description: R21 with ASO1B

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with ASO1B
Description: R21 with ASO1B
Study: NCT03551990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole-body electromyostimulation WB-EMS
Description: Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
Study: NCT01130532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Administer orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Administer orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer orally